News
Cambridge, United Kingdom, 26th July 2023 / Domainex Ltd., a leading, integrated medicines research services partner and recent recipient of the King’s Award for Enterprise in International Trade, announces the purchase of its third, multi-channel Malvern Panalytical WAVEdelta system, powered by Creoptix technology. Simultaneously, Domainex announces the expansion of its biophysical suite of technologies through the purchase of a Malvern Panalytical PEAQ-ITC instrument with MicroCal technology.
San Diego, CA - BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, announced that Charlie Piscitello has joined the company as Chief People Officer.
In this role, Mr. Piscitello will lead the Company’s human resource related functions, including talent management, culture, and diversity, equity, and inclusion, reporting to Tim Schoen, CEO of BioMed Realty, and will be based in BioMed Realty’s San Diego headquarters.
Biocair recently spoke at two industry events, Gene Therapy Development & Manufacturing 2023 and On Helix 2023, where the company provided insight on how to mitigate risk in the cell and gene therapy supply chain.
Cambridge, UK - 26 July 2023 - Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, is relocating to The Works, Unity Campus, located just outside Cambridge, UK. The company is moving from its previous site at the Babraham Research Campus to an over 7,600 sq ft facility to support further growth.
Welcome News:
One Nucleus welcomes the Government's support of Cambridge to continue developing as a destination to attract global investment and talent in life sciences through plans to create aspirational housing and communities for those employed in the sector.
Housing to Match Aspiration:
Having recently attended the London Stem Cell Conference, Oliver Herd, a trainee patent attorney at IP law firm Appleyard Lees IP LLP, reflects on some of the current activity in the stem cell field and how products, methods and consumables can be protected in Europe.
BioIVT’s standardized collection protocols and diverse donor base help facilitate molecular biomarker validation and ensure their clinical utility.
BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced that it will highlight the integral role it is playing in liquid biopsy research at the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Lab Expo. This conference will be held from July 23-27 at the Anaheim Convention Center in Anaheim, CA.
The Health Systems Task Force is a public-private strategic partnership, bought together by Sir Pascal Soriot, CEO of Astrazenca, which gathers other CEOs and leaders from key stakeholders such as:
- GSK
- Merck KGaA
- Novo Nordisk
- Roche
- Samsung Biologicals
- Sanofi
- Karolinska Instituet
- National Health Service England
- the Sustainable Healthcare Coalition
- UNICEF
- The University of Pavia
- World Health Organizaton (WHO)